Community Trust & Investment Co. Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Community Trust & Investment Co. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 79,434 shares of the medical research company's stock after buying an additional 2,194 shares during the period. Community Trust & Investment Co.'s holdings in IQVIA were worth $14,004,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. QRG Capital Management Inc. lifted its position in shares of IQVIA by 51.9% in the 1st quarter. QRG Capital Management Inc. now owns 8,403 shares of the medical research company's stock worth $1,481,000 after purchasing an additional 2,871 shares during the period. Sagespring Wealth Partners LLC increased its stake in shares of IQVIA by 26.2% in the 1st quarter. Sagespring Wealth Partners LLC now owns 5,861 shares of the medical research company's stock worth $1,033,000 after acquiring an additional 1,215 shares in the last quarter. Great Lakes Retirement Inc. increased its stake in shares of IQVIA by 15.2% in the 1st quarter. Great Lakes Retirement Inc. now owns 3,518 shares of the medical research company's stock worth $620,000 after acquiring an additional 463 shares in the last quarter. Sowell Financial Services LLC bought a new stake in IQVIA during the 1st quarter valued at about $305,000. Finally, Hanson & Doremus Investment Management increased its stake in IQVIA by 14.0% during the 1st quarter. Hanson & Doremus Investment Management now owns 11,141 shares of the medical research company's stock valued at $1,964,000 after purchasing an additional 1,366 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of IQVIA stock traded up $0.53 on Thursday, hitting $154.63. 1,667,170 shares of the company's stock were exchanged, compared to its average volume of 1,628,016. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The stock has a market capitalization of $26.75 billion, a PE ratio of 21.07, a PEG ratio of 1.69 and a beta of 1.28. The company has a 50-day simple moving average of $147.79 and a 200-day simple moving average of $176.74.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the previous year, the firm earned $2.54 earnings per share. The company's revenue for the quarter was up 2.5% on a year-over-year basis. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

IQV has been the subject of a number of analyst reports. Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Robert W. Baird reduced their price objective on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Truist Financial reduced their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. UBS Group reduced their price target on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Wall Street Zen lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.